Profile data is unavailable for this security.
About the company
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company’s Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.
- Revenue in USD (TTM)58.90m
- Net income in USD-35.19m
- Incorporated2004
- Employees135.00
- LocationAquestive Therapeutics Inc30 Technology DrWARREN 07059-5166United StatesUSA
- Phone+1 (908) 941-1900
- Fax+1 (302) 636-5454
- Websitehttps://aquestive.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Precigen Inc | 3.96m | -139.56m | 257.82m | 202.00 | -- | 4.78 | -- | 65.06 | -0.5479 | -0.5479 | 0.0154 | 0.1891 | 0.0289 | -- | 5.40 | 19,618.81 | -101.81 | -31.50 | -126.84 | -38.63 | -12.44 | 44.00 | -3,521.68 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
| Eton Pharmaceuticals Inc | 34.68m | -5.48m | 277.74m | 30.00 | -- | 17.38 | -- | 8.01 | -0.2135 | -0.2135 | 1.34 | 0.6186 | 1.03 | 9.44 | 7.63 | 1,155,900.00 | -16.27 | -46.22 | -29.44 | -58.20 | 59.30 | 72.16 | -15.81 | -76.86 | 1.41 | -- | 0.2052 | -- | 48.90 | -- | 89.62 | -- | 26.85 | -- |
| Sanara Medtech Inc | 78.06m | -8.36m | 326.44m | 107.00 | -- | 8.20 | -- | 4.18 | -0.9871 | -0.9871 | 9.24 | 4.55 | 0.9518 | 1.91 | 8.39 | 729,503.40 | -10.33 | -17.73 | -12.37 | -22.07 | 90.16 | 88.08 | -10.86 | -17.13 | 2.02 | -3.44 | 0.4326 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| Amylyx Pharmaceuticals Inc | 196.49m | -259.47m | 355.76m | 384.00 | -- | 1.81 | -- | 1.81 | -3.82 | -3.82 | 2.87 | 2.86 | 0.5479 | 2.56 | 12.64 | 511,679.70 | -72.35 | -- | -84.00 | -- | 78.88 | -- | -132.05 | -- | 4.55 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
| Revance Therapeutics Inc | 247.00m | -180.81m | 402.83m | 597.00 | -- | -- | -- | 1.63 | -1.91 | -1.95 | 2.55 | -1.55 | 0.497 | 1.03 | 6.71 | 413,740.40 | -36.38 | -55.55 | -43.47 | -63.20 | 72.61 | -- | -73.20 | -304.96 | 3.05 | -15.40 | 1.58 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| Aquestive Therapeutics Inc | 58.90m | -35.19m | 411.21m | 135.00 | -- | -- | -- | 6.98 | -0.4514 | -0.4514 | 0.7297 | -0.4982 | 0.6954 | 2.56 | 6.46 | 436,296.30 | -41.55 | -76.63 | -54.06 | -123.85 | 69.39 | 64.24 | -59.75 | -102.95 | 5.91 | -2.72 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| Rigel Pharmaceuticals Inc | 157.47m | 3.88m | 441.08m | 147.00 | 115.56 | -- | 76.07 | 2.80 | 0.2167 | 0.2167 | 8.98 | -0.831 | 1.24 | 3.06 | 5.82 | 1,071,252.00 | 3.05 | -28.82 | 5.10 | -47.26 | 89.43 | 97.88 | 2.46 | -35.76 | 1.87 | 1.69 | 1.32 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| SIGA Technologies Inc | 173.73m | 85.71m | 447.49m | 45.00 | 5.28 | 2.64 | 5.19 | 2.58 | 1.19 | 1.19 | 2.42 | 2.37 | 0.9823 | 0.5034 | 17.25 | 3,860,698.00 | 48.46 | 22.34 | 57.01 | 27.56 | 81.60 | 88.65 | 49.33 | 41.14 | 5.32 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
| Xeris Biopharma Holdings Inc | 187.36m | -63.11m | 452.96m | 377.00 | -- | -- | -- | 2.42 | -0.4388 | -0.4388 | 1.30 | -0.1901 | 0.5775 | 0.8389 | 4.30 | 496,978.80 | -19.45 | -43.60 | -26.81 | -56.57 | 81.36 | 78.23 | -33.69 | -143.08 | 1.29 | -1.86 | 1.14 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
| Theravance Biopharma Inc | 63.19m | -49.40m | 470.14m | 99.00 | -- | 2.55 | -- | 7.44 | -1.01 | -1.01 | 1.29 | 3.78 | 0.1642 | -- | 3.73 | 638,303.00 | -12.84 | -40.51 | -13.71 | -48.50 | -- | -- | -78.18 | -305.27 | -- | -- | 0.1379 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Esperion Therapeutics Inc | 295.45m | -86.77m | 486.68m | 240.00 | -- | -- | -- | 1.65 | -0.6585 | -0.6585 | 1.72 | -1.89 | 1.10 | 0.8275 | 5.35 | 1,231,046.00 | -32.41 | -69.45 | -74.85 | -101.81 | 81.58 | -- | -29.37 | -147.44 | 1.37 | 0.3253 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Zevra Therapeutics Inc | 24.79m | -84.93m | 487.32m | 65.00 | -- | 6.97 | -- | 19.66 | -1.96 | -1.96 | 0.5825 | 1.31 | 0.150 | -- | 2.80 | 381,323.10 | -51.39 | -32.11 | -61.91 | -39.89 | 53.72 | -- | -342.63 | -128.42 | -- | -25.93 | 0.4578 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Emergent Biosolutions Inc | 1.13bn | -208.80m | 509.33m | 1.60k | -- | 1.00 | -- | 0.4525 | -4.10 | -4.10 | 21.19 | 9.40 | 0.6678 | 2.21 | 6.66 | 703,437.50 | -12.39 | -2.94 | -16.86 | -3.66 | 33.51 | 53.24 | -18.55 | -5.95 | 1.47 | -1.20 | 0.5658 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| SNDL Inc | 652.27m | -79.06m | 525.69m | 2.52k | -- | 0.6076 | -- | 0.8059 | -0.3017 | -0.3017 | 2.48 | 3.26 | 0.6062 | 4.98 | 36.38 | 259,248.20 | -7.61 | -24.44 | -8.22 | -27.94 | 25.69 | 22.49 | -12.55 | -62.17 | 4.16 | -- | 0.114 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
| ASP Isotopes Inc | 2.30m | -27.05m | 548.67m | 76.00 | -- | 36.50 | -- | 239.00 | -0.628 | -0.628 | 0.0549 | 0.2112 | 0.068 | -- | -- | 30,206.32 | -71.81 | -- | -89.44 | -- | 36.54 | -- | -1,055.85 | -- | -- | -8.11 | 0.6748 | -- | -- | -- | -229.34 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Aquestive Therapeutics Inc's reporting currency: US Dollar USD
31.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Bratton Capital Management LPas of 30 Sep 2024 | 9.81m | 10.77% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 5.35m | 5.88% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 4.15m | 4.56% |
| Franklin Advisers, Inc.as of 30 Sep 2024 | 2.77m | 3.04% |
| Geode Capital Management LLCas of 30 Sep 2024 | 1.67m | 1.83% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 1.50m | 1.64% |
| Janney Montgomery Scott LLC (Investment Management)as of 30 Sep 2024 | 923.29k | 1.01% |
| Woodline Partners LPas of 30 Sep 2024 | 816.25k | 0.90% |
| Citadel Advisors LLCas of 30 Sep 2024 | 811.78k | 0.89% |
| Invesco Capital Management LLCas of 30 Sep 2024 | 786.58k | 0.86% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
